Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial
| Autor: | William Rosenberg, Eduardo Vilar-Gomez, Naga Chalasani, James Tonascia, Kris V. Kowdley, Laura Wilson, Veeral Ajmera, Katherine P. Yates, Samer Gawrieh, Oscar W. Cummings |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Clinical Trials and Supportive Activities Chronic Liver Disease and Cirrhosis RC799-869 Placebo Gastroenterology Hepatitis Fibrosis Clinical Research Internal medicine medicine Clinical endpoint In patient Liver histology Hepatology business.industry Vitamin E Liver Disease Area under the curve Evaluation of treatments and therapeutic interventions Original Articles Diseases of the digestive system. Gastroenterology respiratory system medicine.disease 6.1 Pharmaceuticals Original Article business Digestive Diseases Pioglitazone medicine.drug |
| Zdroj: | Hepatology communications, vol 5, iss 5 Hepatology Communications Hepatology Communications, Vol 5, Iss 5, Pp 786-797 (2021) |
| Popis: | Enhanced liver fibrosis score (ELF) and one of its components, amino-terminal propeptide of type III procollagen (PIIINP) are promising noninvasive biomarkers of liver histology in patients with nonalcoholic steatohepatitis (NASH). We evaluated the association of ELF and PIIINP with fibrosis stages at baseline and end of treatment (EOT) with vitamin E or pioglitazone in the PIVENS trial (Pioglitazone vs. Vitamin E vs. Placebo for the Treatment of Nondiabetic Patients With NASH) and characterized ELF and PIIINP changes and their associations with changes in the histological endpoints. ELF and PIIINP were measured at baseline and weeks 16, 48, and 96 on sera from 243 PIVENS participants. Baseline and EOT ELF were significantly associated with fibrosis stage (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|